Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Fradley

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Blood Advances|February 12, 2020
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemiaOnyee Chan, Chetasi Talati, Leidy Isenalumhe, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 28, 2020
Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular ToxicitySusan F Dent, Robin Kikuchi, Lavanya Kondapalli, et al.
Cardio-Oncology (London, England)|July 4, 2025
QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2- metastatic breast cancer receiving a CDK4/6 inhibitor in first lineSusan Dent, Heather Moore, Michael Fradley, et al.
The Oncologist|July 30, 2025
Considerations for the Practical Management of Cardiovascular Risk With Bruton's Tyrosine Kinase Inhibitors for Patients With CLLDaniel Lenihan, Michelle Bloom, Robert Copeland-Halperin, et al.
Cardio-Oncology (London, England)|January 28, 2025
CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 - metastatic breast cancerSusan Dent, Avirup Guha, Heather Moore, et al.
Cardio-Oncology (London, England)|November 18, 2025
Real-world analysis of cardiovascular adverse events and risk factors after immune checkpoint inhibitor therapyYanfei Wang, Shu Niu, Bently P Doonan, et al.
Heart Rhythm|October 23, 2025
New-onset atrial fibrillation as a predictor of cancer: Insights from a real-world datasetAshraf Alzahrani, Kaushik Gokul, Aswathi Paleri, et al.
Current Cardiology Reports|February 16, 2023
Cardiovascular Toxicities Associated with Tyrosine Kinase InhibitorsNicolas Sayegh, Juliet Yirerong, Neeraj Agarwal, et al.
Journal of Comparative Effectiveness Research|April 22, 2025
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databasesKerry A Rogers, Benyam Muluneh, Zaina P Qureshi, et al.
Journal of Gastrointestinal Oncology|March 17, 2020
Clinical factors associated with the development of postoperative atrial fibrillation in esophageal cancer patients receiving multimodality therapy before surgeryEthan Y Song, Puja Venkat, Michael Fradley, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Blood Advances|February 12, 2020
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemiaOnyee Chan, Chetasi Talati, Leidy Isenalumhe, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|March 28, 2020
Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular ToxicitySusan F Dent, Robin Kikuchi, Lavanya Kondapalli, et al.
Cardio-Oncology (London, England)|July 4, 2025
QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2- metastatic breast cancer receiving a CDK4/6 inhibitor in first lineSusan Dent, Heather Moore, Michael Fradley, et al.
The Oncologist|July 30, 2025
Considerations for the Practical Management of Cardiovascular Risk With Bruton's Tyrosine Kinase Inhibitors for Patients With CLLDaniel Lenihan, Michelle Bloom, Robert Copeland-Halperin, et al.
Cardio-Oncology (London, England)|January 28, 2025
CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 - metastatic breast cancerSusan Dent, Avirup Guha, Heather Moore, et al.
Cardio-Oncology (London, England)|November 18, 2025
Real-world analysis of cardiovascular adverse events and risk factors after immune checkpoint inhibitor therapyYanfei Wang, Shu Niu, Bently P Doonan, et al.
Heart Rhythm|October 23, 2025
New-onset atrial fibrillation as a predictor of cancer: Insights from a real-world datasetAshraf Alzahrani, Kaushik Gokul, Aswathi Paleri, et al.
Current Cardiology Reports|February 16, 2023
Cardiovascular Toxicities Associated with Tyrosine Kinase InhibitorsNicolas Sayegh, Juliet Yirerong, Neeraj Agarwal, et al.
Journal of Comparative Effectiveness Research|April 22, 2025
A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databasesKerry A Rogers, Benyam Muluneh, Zaina P Qureshi, et al.
Journal of Gastrointestinal Oncology|March 17, 2020
Clinical factors associated with the development of postoperative atrial fibrillation in esophageal cancer patients receiving multimodality therapy before surgeryEthan Y Song, Puja Venkat, Michael Fradley, et al.
Pageof 4